TRCT
BCAX

Tower Research Capital (TRC)’s Bicara Therapeutics BCAX Stock Holding History

Tower Research Capital (TRC)’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.2K Sell
1,488
-976
-40% -$21.8K ﹤0.01% 2841
2026
Q1 		$49K Buy
2,464
+1,780
+260% +$30.6K ﹤0.01% 2754
2025
Q4 		$11.5K Sell
684
-1,117
-62% -$19.1K ﹤0.01% 3584
2025
Q3 		$28.4K Sell
1,801
-2,987
-62% -$33.4K ﹤0.01% 2990
2025
Q2 		$44.5K Buy
4,788
+3,866
+419% +$46.1K ﹤0.01% 3072
2025
Q1 		$12K Sell
922
-134
-13% -$1.78K ﹤0.01% 3479
2024
Q4 		$18.4K Buy
+1,056
New +$22K ﹤0.01% 3256

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s BCAX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Bicara Therapeutics (BCAX) stake by 40% in Q2 2026, selling an estimated $21.8K and leaving 1,488 shares worth $44.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2841.

Tower Research Capital (TRC) first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. The position peaked at $49K in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Tower Research Capital (TRC) held 1,488 shares of Bicara Therapeutics worth $44.2K as of Q2 2026.
  • Tower Research Capital (TRC) sold 976 Bicara Therapeutics shares in Q2 2026, an estimated $21.8K.
  • Bicara Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2841 holding.
  • Tower Research Capital (TRC) first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s Bicara Therapeutics position peaked at $49K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.